grant
Molecular Analyses of Endometrial Cancer
Organization NATIONAL HUMAN GENOME RESEARCH INSTITUTELocation UNITED STATES
NIHUS FederalResearch GrantFY2025ACTRACTRIACVR1ACVR1 geneACVRLK2ACVRLK4AGO ProteinAIB1AKTALK-5 proteinALK-5 receptorALK2ALK5APF-1ATP-Dependent Proteolysis Factor 1Activin A Receptor Type II-Like Kinase 53kDaActivin A Receptor, Type II-Like Kinase 2 GeneActivin Receptor-Like Kinase 2 GeneActivin Receptor-Like Kinase 5AffectAkt proteinAmericanAmerican Cancer SocietyAmplified in Breast Cancer 1Amplified in Breast Cancer 1 ProteinAntibody-drug conjugatesArchipelago HomologueArchipelago Homologue ProteinAssayBasal Transcription FactorBasal transcription factor genesBindingBinding SitesBioassayBiochemicalBiological AssayBiological MarkersBody of uterusBone-Derived Transforming Growth FactorCAGH16CALL proteinCBP-30CBP-35CBP35CCNECCNE1CCNE1 geneCDC4CDK Inhibitor ProteinCDKI ProteinCamL1 Gene ProductCancer CauseCancer EtiologyCancersCarbohydrate-Binding Protein 35CarcinomaCarcinoma CellCell BodyCell Communication and SignalingCell LineCell SignalingCell Surface Glycoprotein L1CellLineCellsCessation of lifeChromosomal, Gene, or Protein AbnormalityClinicalClinical TreatmentClinical TrialsCombining SiteComplexCorpus UteriCorpus Uteri Malignant Mixed Mesodermal TumorCyclin ECyclin Kinase InhibitorCyclin-Dependent Kinase InhibitorCyclin-E1Cytogenetic or Molecular Genetic AbnormalityDNA mutationData SetDeathDevelopmentDiseaseDisorderEndometrial CancerEndometrial CarcinomaEndometrial NeoplasmsEndometrial TumorEndometriumEndometrium CancerEndometrium CarcinomaEndometrium TumorEpithelial cancerEpitheliumEpsilon-Binding ProteinExhibitsF-box and WD-40 domain protein 7F-box protein FBW7F11 GlycoproteinFBW7FBX30FBXW7FBXW7 ProteinFBXW7 geneFLJ11071Fibrodysplasia Ossificans ProgressivaGalectin 3General Transcription Factor GeneGeneral Transcription FactorsGenesGeneticGenetic AbnormalityGenetic ChangeGenetic defectGenetic mutationGenomeGerm LinesGoalsHL-29HMG-20High Mobility Protein 20HistologicHistologicallyHumanIgE Binding ProteinIgEBPIndividualIntracellular Communication and SignalingInvestigationJV18JV18-1KinasesKnock-inL-29 LectinL-31L-34L1 Cell Adhesion MoleculeL1CAML30 LectinLGALS3MADH2MADH2 geneMADR2Mac-2 AntigenMacrophage-2 AntigenMalignant Epithelial CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant NeoplasmsMalignant TumorManuscriptsMediatingMedicineMetabolic Protein DegradationMilk Growth FactorMissense MutationModern ManMolecularMolecular AbnormalityMolecular AnalysisMolecular CarcinogenesisMolecular InteractionMutationNCOA3NCOA3 geneNGF-Inducible GlycoproteinNILE GlycoproteinNILE ProteinNatureNeoplasm of the EndometriumNerve Growth Factor-Inducible Large External GlycoproteinNeural Adhesion Molecule L1Neural Cell Adhesion Molecule L1Newly DiagnosedNuclear Receptor Coactivator 3OncogenicOutcomePathogenicityPathologyPathway interactionsPeptide DomainPhosphoproteinsPhosphorylationPhosphotransferase GenePhosphotransferasesPlatelet Transforming Growth FactorPreparationPrognosisProtein DomainsProtein Kinase BProtein PhosphorylationProtein TurnoverProtein-Serine KinaseProtein-Serine-Threonine KinasesProtein-Threonine KinaseProteinsProteomeProteomicsProto-Oncogene Proteins c-aktRAC-PK proteinRAC3RAC3 proteinReactive SiteReceptor-Associated Coactivator 3RecurrenceRecurrentRegulatory Protein DegradationReporterReportingResearchResearch DesignSEL-10SEL10SKR1SKR4SMAD2SRC3SeriesSerine KinaseSerine-Threonine KinasesSerine/Threonine Protein Kinase GeneSerine/Threonine-Protein Kinase Receptor R4SerousSignal TransductionSignal Transduction SystemsSignalingSomatic MutationSteroid Receptor Coactivator 3Strains Cell LinesStructural ModelsStudy TypeTGF BTGF-betaTGF-beta type I receptorTGF-βTGFBR-1TGFBR1TGFBR1 geneTGFbetaTGFβTNRC16TRAM-1TRAM1Tertiary Protein StructureTestingThreonine KinaseTranscription Factor Proto-OncogeneTranscription factor genesTransforming Growth Factor Beta Receptor ITransforming Growth Factor Beta Receptor Type ITransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTransphosphorylasesTumor PromotionTumor Suppressor ProteinsType I Gene Activin A ReceptorUbiquitinUbiquitin Ligase Component GeneUbiquitin Ligase GeneUnited StatesUterine BodyUterine Body Malignant Mixed Mesodermal NeoplasmUterine Body Malignant Mixed Mesodermal TumorUterine CarcinosarcomaUterine Corpus CarcinosarcomaUterine Corpus Malignant Mixed Mesodermal (Mullerian) TumorUterine Corpus Malignant Mixed Mesodermal NeoplasmUterine Corpus Malignant Mixed Mesodermal TumorUterine Corpus Malignant Mixed Mullerian NeoplasmUterine Corpus Malignant Mixed Mullerian TumorUterine Malignant Mixed Mesodermal NeoplasmUterine Malignant Mixed Mesodermal TumorUterine Mixed Mullerian SarcomaUterine liningUterusVariantVariationWomanbio-markersbiologic markerbiological signal transductionbiomarkerc mycc-akt proteinc-myc Genescancer cell genomecancer genomecell typeclinical interventionclinical relevanceclinical therapyclinically relevantcmyccomputer based predictioncorpus uteri carcinosarcomacultured cell linedevelopmentaldisease causing variantdisease-causing alleledisease-causing mutationdruggable targetendometrial neoplasiaepithelial carcinomagain of functiongenome mutationgenomic toolsin silicoinhibitorinterestkinase inhibitorknockinloss of function mutationmalignancymissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmolecular aberrationsmutantmutation correctionmyositis ossificans progressivaneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyp/CIPpathogenic allelepathogenic variantpathwayphospho-proteomicsphosphoproteomicspre-clinical studypreclinical studypredictive modelingpreparationspreventpreventingprogressive myositis ossificansprogressive ossifying myositisprotein degradationprotein functionproto-oncogene protein RACproto-oncogene protein aktrac protein kinaserelated to A and C-proteinsmall molecular inhibitorsmall molecule inhibitorsomatic variantstudy designthyroid hormone receptor activator molecule 1transcription factortrial regimentrial treatmenttumortumor genometumor suppressorubiquitin ligaseuterine body carcinosarcomauterus carcinosarcomauterus malignant mixed mesodermal neoplasmuterus malignant mixed mesodermal tumoruterus mixed mullerian sarcomav-myc Avian Myelocytomatosis Viral Oncogene Cellular Homologwomb
Description preview
Uterine corpus cancer is the 5th leading cause of cancer death amongst American women. The American Cancer Society predicts that in 2025 there will be ~ 69,120 newly diagnosed cases of uterine corpus cancer and ~13,860 deaths from this disease in the United States. The majority (~98%) of these cancers are endometrial carcinomas (ECs), which arise…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click